A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis.
Phase of Trial: Phase III
Latest Information Update: 09 May 2012
At a glance
- Drugs Tetomilast (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 09 May 2012 Company (Otsuka Pharmaceutical Development and Commercialization) added as reported by ClinicalTrials.gov.
- 09 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00064454).
- 25 Aug 2011 Actual initiation date changed from 7 Sep 2005 to 24 Oct 2005 as reported by European Clinical Trials Database.